

Special Issue

Amyloidosis: Structure-Based Therapeutic Development and Prevention

Message from the Guest Editor

Amyloidosis is a hallmark of a number of diseases that affect different body tissues and organs including the brain, nervous system, heart, kidneys, blood, pancreas, digestive system, skin, etc. It presents aggregation and deposition of an abnormal protein, denoted as amyloid, thus causing significant issues in the affected areas. Structure-based drug design is one of the most state-of-the-art approaches in computer-aided drug design (CADD). Molecular docking and virtual screening are widely applied methods for the discovery of new molecules and their structure optimization within the binding site of the target macromolecule, as they reveal the intimate mechanism of interaction between the two partners. This Special Issue aims to focus on the application of a structure-based drug-design approach in the field of amyloidosis. We welcome articles applying these methods for the identification and development of promising anti-amyloid drug candidates as well as for unveiling any intimate mechanism of the dynamic interaction involving amyloid peptide.

Guest Editor

Prof. Dr. Mariyana Atanasova

Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria

Deadline for manuscript submissions

closed (30 September 2023)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/129659

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)